Laserfiche WebLink
M.NETWORK <br />51RFP NO. 19-07-02 <br />7. CREATIVE ABILITY <br />The firm shall submit an example of their most recent branding or re-branding campaign <br />along with research and results. The firm shall submit 1-3 samples of past branding or <br />publicity results, preferably government or non-profit, and indicate the approach taken for <br />the development of those examples. The work should show the breadth of capabilities for <br />the Firm regarding brand development and implementation; firm may provide examples for <br />creative for other industries and clients. The firm should include any demonstrated use of <br />creative technology to implement PR programs. <br />As you have already seen from the case studies provided, The M Network uses a research- <br />based methodology for virtually every client we have. The 5 examples we’ve provided are <br />specifically for government and non-profit clients and clearly demonstrate our “Brand First” <br />approach. Each case study was selected to show the work we created, demonstrate our <br />breadth of capabilities, show off our innovative thinking, and demonstrate our proven results. <br />You may refer back to these examples in sections 2g and 2h of our response. <br />One additional case study that we can point to in order to demonstrate our ability to utilize <br />cutting edge technology to target an audience falls outside of our government and non-profit <br />work. <br />Ferring Pharmaceuticals <br />Ferring Pharmaceuticals is the manufacturer of the advanced prostate cancer treatment, <br />Firmagon. Unlike other advanced prostate cancer treatments, Firmagon does not have the <br />same cardio vascular risk profile as its competitors. <br />Ferring called on The M Network last year to help develop and execute a campaign to <br />highlight this difference. The campaign would not only need to be verifiably effective, it would <br />also have to pass through strict medical and legal review in order to be approved. <br />In our preliminary research, we found that all advanced prostate cancer treatments are <br />prescribed by the doctor. We also found that 70% of all doctors treating advanced prostate <br />cancer were Urologists. We also found that there are only about 12,500 Urologists practicing <br />in the U.S. This incredibly small target audience, spread out across the entire country, meant <br />we had to be clever in how, when, and with what message we reached them.